1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On July 27, 2026, Hawaiian Electric Company and Kalaeloa Partners entered a new power purchase agreement for 208 megawatts of firm capacity over a 30-year term after commercial operation, replacing the October 2021 agreement that is expected to end in early 2033. The fixed capacity charge falls to $93 per kilowatt per year from $100, and the deal lets Kalaeloa repower the plant to burn other fuels and produce renewable-qualifying energy. The agreement takes effect only after the Hawaii Public Utilities Commission approves it.
New PPA signed July 27, 2026, for 208 MW of firm capacity over a 30-year term after commercial operation
Fixed capacity charge reduced to $93/kW per year from $100/kW per year under the Amended and Restated PPA
Effectiveness depends on PUC approval; either party may void the agreement if approval is not received within 12 months of the application, subject to conditions
Aldeyra Therapeutics executed a lease on July 28, 2026 for about 4,067 square feet of office space at 23 Bradford Street in Concord, Massachusetts, to serve as its corporate headquarters. The lease starts September 1, 2026 and runs through September 30, 2029, with monthly base rent of $12,201.00 plus operating expenses and taxes. This is a routine administrative agreement with limited direct financial effect on shareholders.
Lease covers about 4,067 square feet at 23 Bradford Street, Concord, Massachusetts, with Bradford Street, L.L.C.
Term begins September 1, 2026 and ends September 30, 2029; base rent is $12,201.00 per month and increases annually.
Company will post an initial security deposit of $50,000.00 and pay additional operating expenses, taxes and fees.
Ambow Education Holding Ltd. announced general availability of the HybriU AI Adaptive Course Generation Platform, a new product within its HybriU AI-powered platform, on July 30, 2026. The filing describes the product as a way to turn any topic or body of institutional knowledge into a personalized learning application, and it is the third HybriU product launch of 2026. The filing contains no financial results, pricing or revenue figures, so the launch's effect on shareholders cannot be measured from this document.
Product made generally available globally on July 30, 2026 through desktop and mobile web
Filing cites Grand View Research projection that the global corporate training market will reach $458 billion in 2026
Third HybriU product launch of 2026, following HybriU Collaboration Board and HybriU ProjectHub
No revenue, pricing or financial figures disclosed; enterprise pricing inquiries directed to ir@ambow.com
Tvardi Therapeutics said it selected ulcerative colitis (UC) as the initial disease indication for its oral STAT3 inhibitor TTI-109, following a completed Phase 1 healthy volunteer study. The company plans a UC clinical trial in 2027, subject to IND clearance and additional funding, and will host a key opinion leader webinar on August 19, 2026.
Phase 1 healthy volunteer study showed placebo-adjusted reductions in immune cell subsets, including up to 76% reduction in Th17-associated populations.
Company cites an addressable market of approximately $3 billion in the U.S. and $9 billion globally for UC.
Planned UC trial start in 2027 is subject to IND clearance and additional funding, and the company has not stated amounts of additional funding needed.
KOL webinar with Dr. Randy Longman is scheduled for Wednesday, August 19, 2026 at 11:00 AM ET.
Cadiz's subsidiary Fenner Gap Mutual Water Company signed two construction manager at risk agreements on July 27, 2026, with guaranteed maximum prices totaling about $273.8 million for the Northern Pipeline. The company estimates total construction capital expenditures to place the pipeline into service at about $403.3 million, so the agreements cover most of the estimated cost and set a defined budget for the Mojave Groundwater Bank financing.
Lyles Agreement: guaranteed maximum price of about $218.9 million for pump-station facilities, with 15% project contingency.
Bubalo Agreement: guaranteed maximum price of about $54.9 million for pipeline replacement, with 10% project contingency.
Estimated total construction capital budget is about $403.3 million, including $129.5 million for owner-procured equipment and other items.
Construction starts after notices to proceed and financing and permitting conditions are met; the agreements assume a September 2026 notice to proceed.
BioNexus issued a press release describing progress toward commercializing the VitaGuard MRD platform in Southeast Asia following a working visit to Tongshu Gene facilities in China. The filing contains no financial results, new agreements or financial commitments, and it states that no definitive agreement has been executed for markets outside Southeast Asia.
Visit to Tongshu Gene facilities in Shanghai and Changzhou, China, led by Fidelion Chief Commercial Officer Dr. Muthu Meyyappan
Company continues to target initial deployment in select Southeast Asian medical hubs during 2026, subject to work and approvals
Work is underway in Malaysia and Singapore; Fidelion is in discussions with prospective partners outside Southeast Asia, with no definitive agreement executed
BioNexus owns approximately 15% of Fidelion Diagnostics
ProMIS Neurosciences reported blinded six-month interim safety and biomarker data for PMN310 in its Phase 1b PRECISE-AD trial in early Alzheimer's disease, with no ARIA-E cases reported across 136 safety-evaluable patients. The trial remains blinded and ongoing, and the company said unblinded 12-month topline results, including efficacy data, are expected in the first quarter of 2027. The filing contains no financial results, so the update is clinical data that shareholders will weigh ahead of the readout.
No ARIA-E reported as of the July 22, 2026 data cutoff; 4.4% total ARIA, all mild and asymptomatic (ARIA-H only)
68.5% of patients had a plasma pTau217 decline from baseline and 62.5% had a CSF MTBR-tau243 decline; the company says allocations are still blinded
Unblinded 12-month topline results expected in Q1 2027, including efficacy data
Webinar held July 28, 2026 at 8:00 a.m. E.T. with KOLs Dr. Will Mantyh and Dr. Michael Weiner
Kyverna Therapeutics and ElevateBio signed a Clinical and Commercial Supply Agreement on July 23, 2026, replacing their prior manufacturing agreement in its entirety. The deal covers clinical and commercial supply of Kyverna's lead candidate, miv-cel, and requires Kyverna to order minimum quantities in certain years and/or after FDA approval. The filing does not disclose dollar values, so shareholders cannot yet gauge the financial scale of the commitment.
Agreement signed July 23, 2026, and replaces the prior agreement with ElevateBio in its entirety.
Initial term of five years, with automatic one-year renewals unless terminated under the agreement's terms.
Prices and fees are subject to an annual inflation adjustment up to a maximum percentage, tied to the PPI for Pharmaceutical Preparation Manufacturing.
Full agreement to be filed with the Form 10-Q for the quarter ending September 30, 2026; certain terms will be confidential.
Wynn Resorts disclosed that the Macau Government published an amended and restated land concession contract for its Cotai Land on July 22, 2026 Hong Kong time. The amendment permits Wynn Palace to expand with a new five-star hotel, a theater and an event and entertainment center. Palo must pay a one-time additional land premium of approximately $80.8 million, which the Macau subsidiary's announcement says will be paid out of available cash.
One-time additional land premium of MOP652.3 million (approximately $80.8 million), paid upon acceptance of the conditions and satisfied out of available cash
Total annual rent for the Expanded Resort of MOP9.5 million (approximately $1.2 million), subject to review every five years
Palo has a maximum of 60 months from publication to complete development of the Expanded Resort
Lease on the Cotai Land runs from May 2, 2012 until May 1, 2037, with renewal rights subject to applicable legislation
QuantumScape's subsidiary amended its collaboration agreement with PowerCo, Volkswagen Group's battery cell company, on July 16, 2026. The amendment replaces the prior statement of work and cost reimbursement structure with milestone-based payments, with a maximum aggregate amount of $75.4 million inclusive of amounts paid to date. Shareholders may track how the milestone-linked payments and the transfer of QSE-5 Technology progress.
Amendment dated July 16, 2026 updates program structure and milestones for QSE-5 Technology development and initial commercialization
Maximum aggregate amount the Company will receive from PowerCo for the program is $75.4 million, including amounts paid to date
Statement of Work No. 1 was terminated effective July 16, 2026 and replaced by the Amendment; outstanding invoiced obligations remain payable to the Company
On July 17, 2026, Aether Holdings and its subsidiary Aether Compute LLC signed agreements with Virtual Grid Inc. that make Aether Compute the exclusive white-label distributor for Virtual Grid products in ten Southeast Asian territories for an initial ten-year term, and that give Aether Holdings an equity and warrant investment in Virtual Grid for $360,000. The filing states that the company itself is not a party to the supply or license agreements and has no related liability, and that CEO Timothy Murphy is a director and shareholder of Virtual Grid.
Aether Holdings pays the $360,000 subscription price by issuing 82,606 common shares at a Nasdaq Minimum Price of $4.358 per share.
Aether Compute's exclusive territory covers Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam, with a ten-year initial term.
Aether Compute must pay Virtual Grid royalties of 6% of direct gross compute revenue plus a support fee of 20% of the royalty for direct deployments.
Virtual Grid agreed to a 12-month lock-up on the Aether Shares, and the Supply Agreement sets no minimum purchase obligation unless stated in order documents.
Medifast, Inc. announced on July 17, 2026 that its wholly owned subsidiary OPTAVIA is being rebranded as Trilivy, described as a comprehensive metabolic health system. The company also introduced newly formulated meal replacements, with the planned debut of these Fuelings in August. The filing, which furnishes a press release, includes no revenue, earnings, or guidance figures, so its direct financial effect on shareholders is not quantified.
Rebranding of OPTAVIA to Trilivy announced July 17, 2026, via a press release furnished as Exhibit 99.1
Trilivy Reset Fueling line, enhanced with MetaVantage Technology, accompanies the brand launch
Newly formulated meal replacements, called Fuelings, are planned to debut in August
The filing contains no financial results, guidance, or dollar figures
West Pharmaceutical Services entered into an amended and restated crosslicense agreement and two distributorship agreements with Daikyo Seiko, effective July 14, 2026, which the company says are substantially similar to the 2017 agreements as amended in 2018 and 2019. West holds a 49% ownership interest in Daikyo, and the filing describes the agreements as sharing know-how and granting licenses for pharmaceutical packaging and delivery components, with each agreement running 10 years.
Agreements are effective July 14, 2026 and each has a 10-year term
West is the exclusive distributor of Daikyo products outside Japan, subject to limited exceptions
Daikyo is a non-exclusive distributor of West products in Japan
Full agreement texts will be filed as redacted exhibits to the 10-Q for the quarter ending September 30, 2026
Syndax Pharmaceuticals held an R&D event on July 14, 2026, and disclosed two pipeline additions: SNDX-4321, an externally licensed EGFR inhibitor for non-small cell lung cancer, and SNDX-62122, a next-generation menin inhibitor selected for myelofibrosis. The filing furnishes the press release and presentation but gives no new financial results, and it sets out development timelines, including a Phase 2 axatilimab trial in IPF with topline data expected in 4Q26.
SNDX-4321: IND submission expected by end of 2026 and Phase 1 trial in EGFR-mutated NSCLC planned for 2027; Syndax holds an exclusive worldwide license.
SNDX-62122 is the first candidate from Syndax's wholly owned next-generation menin inhibitor library; a revumenib Phase 1/2 proof-of-principle trial in myelofibrosis is expected to start in 4Q26.
Phase 2 trial of axatilimab in IPF remains on track for topline data in 4Q26.
Presentation states Revuforj and Niktimvo were each annualizing at about $200 million as of 1Q26.
Tactile Systems Technology (Tactile Medical) entered an exclusive U.S. distribution agreement with ElastiMed for the MyoSleeve wearable compression device, covering Department of Veterans Affairs and Department of Defense patients. The company paid an upfront $3 million and committed to certain minimum purchase obligations and marketing support, and the filing gives no revenue or financial outlook for the deal.
Exclusive U.S. distribution rights for MyoSleeve within the VA and DoD systems, announced July 13, 2026
Upfront payment of $3 million to ElastiMed, plus undisclosed minimum purchase and marketing commitments
MyoSleeve has FDA 510(k) clearance for chronic swelling, including chronic edema, lymphedema and venous insufficiency
Alliance Resource Partners disclosed a Master Supply, Distribution and Services Agreement, dated July 1, 2026, between its subsidiary Matrix Design Africa and Saminco Solutions LLC. The Supplier is affiliated with Joseph W. Craft III, who leads the managing general partner, so the deal is a related-party transaction that the Conflicts Committee approved and determined to be fair and reasonable to unitholders. The filing does not disclose a purchase value.
Agreement dated July 1, 2026, between Matrix Design Africa (PTY) LTD and Saminco Solutions LLC, covering products and services in Africa and other territories outside the United States
Initial term of five years, renewing automatically for one-year periods unless either party gives at least 30 days' notice; either party may terminate without cause on at least 90 days' notice
Supplier is affiliated with Joseph W. Craft III, who beneficially owns about 14.6% of common units and is President, CEO and Chairman of the managing general partner; the Conflicts Committee approved the agreement
Praxis Precision Medicines entered a research collaboration and license agreement with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide, its essential tremor candidate. The company also made an equity investment in Remagine, and says the transdermal option could broaden the patient population and strengthen the drug's competitive position.
Agreement announced July 7, 2026, with Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems
Remagine's platform is designed for precise, multi-day active transdermal dosing of ulixacaltamide for essential tremor
Praxis made an equity investment in Remagine; the filing does not disclose the amount or financial terms
The patch is intended to complement the company's lead oral program for ulixacaltamide
21Shares US LLC, the sponsor of the 21Shares Sui ETF, gave CF Benchmarks notice on June 30, 2026 that it is terminating the licensing agreement for the CME CF Sui Dollar Reference Rate, effective August 31, 2026. The sponsor plans to license FTSE index data on or about August 24, 2026, as part of a broader move to a new benchmark provider. Because the benchmark is used to value the trust's shares daily and to calculate net asset value, shareholders will be affected by this change of provider.
Sponsor gave termination notice to CF Benchmarks on June 30, 2026, effective August 31, 2026
Terminated agreement covers the CME CF Sui Dollar Reference Rate, New York Variant, used to value shares and calculate NAV
Sponsor intends to enter a licensing agreement with FTSE International Limited on or about August 24, 2026
FTSE license is expected to have a one-year initial term that renews automatically
The fund's sponsor, 21Shares US LLC, gave notice on June 30, 2026 that it is terminating its licensing agreement with CF Benchmarks, effective August 31, 2026. The benchmark is used to value the Trust's shares daily and calculate its net asset value, so the change affects how the fund is priced. The sponsor plans a replacement license with FTSE International Limited on or about August 24, 2026.
Notice of termination given to CF Benchmarks Ltd. on June 30, 2026, effective August 31, 2026.
Terminated agreement covers the CME CF Solana-Dollar Reference Rate - New York Variant, used to value shares daily and calculate net asset value.
Sponsor intends to license FTSE index data from FTSE International Limited on or about August 24, 2026, with a one-year initial term.
The sponsor of the ARK 21Shares Bitcoin ETF gave notice on June 30, 2026 that it will terminate its licensing agreement with CF Benchmarks, effective August 31, 2026. The fund uses the CME CF Bitcoin Reference Rate to value its shares daily and calculate net asset value, so it plans to replace it with FTSE index data under a new license expected around August 24, 2026.
Termination notice given to CF Benchmarks on June 30, 2026, effective August 31, 2026
Pricing benchmark being replaced is the CME CF Bitcoin Reference Rate—New York Variant
Sponsor intends to sign a new license with FTSE International Limited on or about August 24, 2026
Filing says the switch is part of a broader transition to a new benchmark provider; no financial impact figures are given
The Sponsor, 21Shares US LLC, notified CF Benchmarks on June 30, 2026 that it is terminating the licensing agreement for the XRP pricing benchmark used to value the Trust's shares and calculate its net asset value, effective August 31, 2026. The Sponsor plans to replace it with a licensing agreement with FTSE International Limited on or about August 24, 2026, as part of a broader move to a new benchmark provider.
Notice of termination given to CF Benchmarks on June 30, 2026; termination effective August 31, 2026
Terminated agreement covers the CME CF XRP-Dollar Reference Rate, New York Variant, used daily for share valuation and NAV
Sponsor intends to license FTSE index data on or about August 24, 2026, with a one-year initial term that renews automatically
The sponsor, 21Shares US LLC, gave CF Benchmarks notice on June 30, 2026 that it is terminating the licensing agreement for the CME CF Ether-Dollar Reference Rate used to value the trust's shares and calculate its net asset value. The sponsor intends to replace it with a license from FTSE International Limited on or about August 24, 2026, as part of a broader move to a new benchmark provider.
Termination of the CF Benchmarks pricing benchmark license is effective August 31, 2026
Notice to CF Benchmarks was provided June 30, 2026
Sponsor intends to enter a FTSE International Limited license on or about August 24, 2026, with a one-year initial term that auto-renews
The benchmark is used daily to value trust shares and calculate net asset value
The sponsor of the 21Shares Dogecoin ETF (TDOG) gave notice on June 30, 2026 that it will terminate its licensing agreement with CF Benchmarks, effective August 31, 2026. The index is used to value the trust's shares daily and calculate its net asset value, so the change affects how the fund is priced; the sponsor plans a replacement license with FTSE International Limited on or about August 24, 2026.
Notice of termination given to CF Benchmarks on June 30, 2026; termination effective August 31, 2026
Terminated agreement covers the CF Dogecoin-Dollar US Settlement Price Index, used to value shares and calculate net asset value
Sponsor intends to license FTSE index data on or about August 24, 2026, with a one-year initial term that renews automatically
SAB Biotherapeutics announced that Breakthrough T1D has awarded a grant to Michael J. Haller, M.D., University of Florida, to support the PRISE-hATG clinical study of SAB-142 in patients with Stage 3 type 1 diabetes who are 100 days to 2 years from diagnosis. SAB BIO will co-fund the study, which extends its clinical evaluation of SAB-142 beyond the Phase 2b SAFEGUARD trial; the filing gives no financial amount for the grant or the company's share of costs.
Breakthrough T1D awarded the grant to Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida, dated July 7, 2026.
PRISE-hATG evaluates SAB-142 in patients 100 days to 2 years from a Stage 3 T1D diagnosis.
SAB BIO will co-fund the study alongside the complementary Phase 2b SAFEGUARD trial.
The filing does not disclose grant or co-funding amounts.
Broadcom and Apple agreed to extend their long-standing technology collaboration through 2031 under new multi-year agreements. Broadcom will develop and supply custom ASIC silicon products for multiple generations of Apple products, but the filing does not disclose financial terms.
Agreements extend the Broadcom-Apple collaboration through 2031.
Broadcom will develop and supply a range of custom ASIC silicon products for multiple generations of Apple products.
The filing gives no dollar value, revenue estimate or contract length beyond the 2031 timeframe.
Effective July 1, 2026, the fund entered an Administrative Services Agreement with its adviser, Bluerock Fund Advisor, LLC, to cover administrative work tied to its shift from institutional investment funds into direct real estate holdings. The fund will pay a fee of 0.20% of average managed assets, but the adviser has voluntarily waived a portion equal to the fee on assets held in institutional investment funds, which the filing says is about 53% of the fee owed. The fund also said it had closed about $250 million of direct real estate investments and had about $450 million under contract or in its pipeline as of July 1, 2026.
Administrative Services Agreement dated July 1, 2026, with Bluerock Fund Advisor, LLC; fee of 0.20% of average managed assets, payable monthly from July 1, 2026
Adviser waives approximately 53% of the fee, based on investments as of July 1, 2026
As of July 1, 2026: about $250 million of direct real estate investments closed; about $450 million under contract or in pipeline
Agreement can be terminated on 60 days' written notice without penalty
Q/C Technologies gave notice on June 26, 2026 that it was terminating its Technology License and Development Agreement with LightSolver Ltd., effective the same day. The company said it has decided to focus fully on its optical processing unit initiative for AI inference, and the filing gives no financial figures for the termination. Shareholders should note that LPU Holdings is relieved of any further milestone payments to LightSolver.
License terminated effective June 26, 2026, after notice was given that day
LPU Holdings is no longer obligated to make additional milestone payments to LightSolver
Optical processing unit initiative was launched March 18, 2026
On June 30, 2026, the company announced a headquarters move to San Francisco with a 4,800-square-foot integrated photonics laboratory
Avalyn Pharma entered a First Amendment to its sublease with CRISPR Therapeutics, effective June 29, 2026, expanding the Boston premises from about 8,774 to about 13,708 rentable square feet. The amendment raises the company's future minimum lease payments by approximately $924,000 over the remaining lease term, a modest commitment that shareholders may want to note.
Effective date: June 29, 2026; the sublease covers 105 West First Street, Boston, Massachusetts
Premises expand from approximately 8,774 to approximately 13,708 rentable square feet
Future minimum lease payments increase by approximately $924,000 over the remaining lease term
All other terms of the original August 29, 2025 sublease remain in effect
Jade Biosciences entered into a license agreement with Paragon Therapeutics on June 29, 2026, granting it exclusive worldwide rights to certain monospecific antibodies and products targeting an undisclosed target. The company must pay Paragon milestone payments of up to $22.0 million, sublicensing fees of up to approximately $20.1 million, and royalties on net sales, which shows the financial commitments tied to the program.
Agreement dated June 29, 2026; Jade already paid a $1.5 million candidate nomination fee in January 2026.
Milestones total up to $22.0 million, including a $2.5 million payment upon first human dosing in a Phase 1 trial.
Royalties of low to mid-single-digit percentage on monospecific product sales and mid-single-digit on multispecific product sales.
Paragon will not run new campaigns generating monospecific antibodies against the Target for at least five years; full text to be filed with the 10-Q for the quarter ending June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.